Feasibility of gadofosveset-enhanced 3.0T cardiac MRI: quantitative comparision with non-enhanced cardiac MRI at 3.0T and 1.5T.

Feasibility of gadofosveset-enhanced 3.0T cardiac MRI: quantitative comparision with non-enhanced cardiac MRI at 3.0T and 1.5T. - gadofosveset-enhanced cardiac MRI at 3.0T

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30231

Enrollment

Registered

2006-09-07

Start date

2007-04-12

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac failure ischemic heart disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: scheduled cardiac MRI for suspected ischemic heart disease age: > 18 years en

Exclusion criteria

Exclusion criteria: severe cardiac rhythm disturbances hemodynamic unstable contra-indications for contrast-enhanced MRI: absolute: pacemaker, pacemakerwires, implanted hearing aid, cerebral vascular clips. Relative contra-indications: neurostimulator, insulinpump, metal corpora aliena, claustrophobic patients, pregnancy, previous reaction on MR contrast agents age: 90 years

Design outcomes

Primary

Measure	Time frame
differences in objective and subjective MRI-image parameters between 1.5T and 3T (artefacts, signal-to-maise ratio, signal and contrast before, during and after administration of contrast agent, subjective image quality, location and extent of contrast agent uptake in the wall of the left ventricle).	—

Countries

Netherlands

Outcome results